0001209191-19-030040.txt : 20190515 0001209191-19-030040.hdr.sgml : 20190515 20190515164225 ACCESSION NUMBER: 0001209191-19-030040 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190513 FILED AS OF DATE: 20190515 DATE AS OF CHANGE: 20190515 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PRASAD SUYASH CENTRAL INDEX KEY: 0001679129 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37833 FILM NUMBER: 19829052 MAIL ADDRESS: STREET 1: C/O AUDENTES THERAPEUTICS, INC. STREET 2: 101 MONTGOMERY ST., SUITE 2650 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Audentes Therapeutics, Inc. CENTRAL INDEX KEY: 0001628738 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 461606174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 600 CALIFORNIA ST., 17TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94108 BUSINESS PHONE: 415-638-6556 MAIL ADDRESS: STREET 1: 600 CALIFORNIA ST., 17TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94108 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-05-13 0 0001628738 Audentes Therapeutics, Inc. BOLD 0001679129 PRASAD SUYASH C/O AUDENTES THERAPEUTICS, INC. 600 CALIFORNIA STREET, 17TH FLOOR SAN FRANCISCO CA 94108 0 1 0 0 Senior VP & Chief Med Officer Common Stock 2019-05-13 4 M 0 10000 0.79 A 28236 D Common Stock 2019-05-13 4 S 0 9946 36.9758 D 18290 D Common Stock 2019-05-13 4 S 0 54 37.72 D 18236 D Stock Option (right to buy) 0.79 2019-05-13 4 M 0 10000 0.00 D 2024-02-18 Common Stock 10000 30870 D This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Represents the weighted average sale price. The lowest price at which shares were sold was $36.61 and the highest price at which shares were sold was $37.46. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in this footnote. The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events. /s/ Thomas Soloway, as attorney-in-fact for Suyash Prasad 2019-05-15